Latin America Pulmonary Arterial Hypertension Market Size & Outlook
Latin America pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Latin America pulmonary arterial hypertension market highlights
- The Latin America pulmonary arterial hypertension market generated a revenue of USD 687.5 million in 2023.
- The market is expected to grow at a CAGR of 5.7% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2024 to 2030.
Latin America data book summary
| Market revenue in 2023 | USD 687.5 million |
| Market revenue in 2030 | USD 1,015.1 million |
| Growth rate | 5.7% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Latin America region accounted for 9.3% of the global pulmonary arterial hypertension market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,501.9 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.42% in 2023. Horizon Databook has segmented the Latin America pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The market in Latin America is expected to show gainful growth over the forecast period. Increasing government & per capita health spending and continual initiatives being undertaken by the WHO & the government are expected to boost the market growth in Latin America. The steadily increasing prevalence of obesity and Type-2 diabetes is expected to be a prominent market driver during the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America pulmonary arterial hypertension market size, by country, 2018-2030 (US$M)
Latin America Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
